Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 7/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GCG | P01275 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.32 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.32 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.32 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.32 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.32 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659417 | 0.92 | GCGR (0.63) | GCGRTRPV1BTKGCGCHRM5 | |
| SCHEMBL2660395 | 0.87 | GCGR (0.52) | GCGRTRPV1NPC1RAB9AKMT2A | |
| SCHEMBL13818504 | 0.86 | GCGR (0.51) | GCGRTRPV1NPC1RAB9AXDH | |
| SCHEMBL2660245 | 0.86 | GCGR (0.53) | GCGRTRPV1BTKNPC1RAB9A | |
| SCHEMBL2660439 | 0.85 | GCGR (0.43) | GCGRTRPV1BTKNPC1RAB9A | |
| SCHEMBL2659677 | 0.84 | GCGR (0.75) | GCGRTRPV1BTKGCGCHRM5 | |
| SCHEMBL2659756 | 0.83 | GCGR (0.59) | GCGRTRPV1BTKGCGCHRM5 | |
| SCHEMBL2660060 | 0.79 | GCGR (0.57) | GCGRGCGCHRM5GLP1R | |
| SCHEMBL2659934 | 0.79 | GCGR (0.53) | GCGRTRPV1BTKNPC1RAB9A | |
| SCHEMBL1765183 | 0.78 | GCGR (0.68) | GCGRGCGCHRM5GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156655-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-06-18 | — | — | US | claimed |
| EP-1957068-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly & Company (US) | 2008-08-20 | — | — | EP | claimed |
| WO-2007120270-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | WO | claimed |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| EP-1957068-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-1957068-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-08-13 | — | — | EP | disclosed |
| US-8691856-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691856-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2014-04-08 | — | — | US | disclosed |
| US-20090156655-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-06-18 | — | — | US | disclosed |
| US-20090156655-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-06-18 | — | — | US | disclosed |
| US-20090156655-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2009-06-18 | — | — | US | disclosed |
| EP-1957068-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly & Company (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007120270-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120270-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156655-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | GLP1R, GCGR, GIPR | GCGR 2/4885TRPV1 658/4885BTK 1425/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885TRPV1 870/4885BTK 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.